Upcoming catalysts in the second quarter of 2024 include US approval decisions on the vaccine V116 for the prevention of invasive pneumococcal disease and pneumococcal pneumonia, the small-molecule drug ensifentrine (RPL554) for chronic obstructive pulmonary disease (COPD) and the bispecific antibody tarlatamab for advanced small-cell lung cancer (SCLC).

The author declares no competing interests.